ProHeal Pharma Secures Tens of Millions RMB in Pre-A Financing Led by Yuansheng Venture and Haisong Capital

PEDaily (ID: pedaily2012) reported on June 25 that recently, Pulekang Pharmaceutical announced the completion of a Pre-A round financing worth tens of millions of RMB. This round of financing was led by`YuanBio Venture Capital`, Haison Capital co-led the investment, Lingjun Venture Capital,Oriza HoldingsCo-invested. Previously securedGuohong Venture CapitalExclusive angel round financing. The proceeds from this round will be used to advance the company's current ophthalmic drug program into the clinical trial phase and to develop new product lines.

Founded in 2019, Pulekang Pharmaceuticals is dedicated to developing innovative therapeutics with novel mechanisms of action to address unmet clinical needs in ophthalmology and autoimmune diseases. Its core founding team comprises overseas-trained pharmaceutical professionals with over a decade of experience at globally renowned pharmaceutical companies such as Allergan, Pfizer, and Johnson & Johnson. The team's expertise spans the entire drug R&D process, and its members have successfully developed multiple large-molecule biologics and small-molecule chemical drugs. Currently, Pulekang Pharmaceuticals is focusing on the development of novel drugs for immune-mediated ocular diseases, with a comprehensive pipeline strategically covering conditions from the ocular surface to the fundus, as well as orbital diseases. Within a relatively short timeframe, the company has advanced several internally developed molecules to the CMC and preclinical research stages and plans to sequentially submit Investigational New Drug (IND) applications in the near future.

Dr. Guo Shuhua, Co-founder and Chairman of Pulekang Pharmaceutical, stated: “We are deeply grateful for the recognition and support from lead investors YuanBio Venture Capital and Haisong Capital, as well as other investing institutions in this financing round. Our team will continue to strive to provide, at the earliest opportunity, ophthalmic drugs that are urgently needed yet in short supply for clinical practice. May all people enjoy health and clear vision.”

The lead investor for this round, YuanBio Venture CapitalPartnerMr. Li Guochun stated: “We are delighted to co-lead the Pre-A financing round of Pulukang Pharmaceuticals. We believe that under the leadership of Dr. Guo, by focusing on R&D in immunology-related ophthalmology, the company will emerge as a new force in the ophthalmology sector. We look forward to the Pulukang team’s continuous innovation in ophthalmic therapeutics, delivering more precise products and services to clinicians and patients with significant unmet clinical needs. YuanBio Venture Capital will continue to accompany and support Pulukang Pharmaceuticals throughout its journey!”

Mr. Chen Liguang, CEO and Managing Partner of Haisong Capital, the lead investor, stated: "The ophthalmology sector represents a highly promising market. Currently, many ophthalmic diseases still lack effective treatment regimens, leaving significant unmet clinical needs. Pulikang Pharmaceutical has strategically positioned itself in the ophthalmology field, advancing multiple product pipelines with substantial clinical value. These pipelines hold best-in-class potential. We are highly optimistic about the company's growth prospects in this sector. Haisong Capital is honored to serve as the lead investor in this round to support Pulikang, standing at the forefront of innovation alongside the company and growing with it."